ARV-393 study in relapsed/refractory Non-Hodgkin lymphoma is recruiting
ClinicalTrials.gov lists a Phase 1 study of ARV-393 in relapsed/refractory Non-Hodgkin lymphoma as recruiting, with monotherapy and combination arms and safety-focused early outcomes.
A Phase 1 study of ARV-393 in relapsed/refractory Non-Hodgkin lymphoma is recruiting, according to a ClinicalTrials.gov registry observation published 2026-11-20T00:00:00+00:00. For people watching new cancer studies, that means the trial is open and still in the early safety-and-dose-testing stage, not at the results stage yet.
The registry lists Arvinas Inc. as sponsor and says has_results is false. It also gives a primary_completion_date of 2028-12, which signals that this is still a long way from any final readout.
ClinicalTrials.gov registry observation, published 2026-11-20T00:00:00+00:00. Registry observation: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. (PHASE1, RECRUITING). Source-record fields: {"phase": "PHASE1", "sponsor": "Arvinas Inc.", "overall_status": "RECRUITING", "has_results"
What the study is testing
The study is organized into four experimental parts: Part A Monotherapy Dose escalation, Part B Monotherapy: Dose expansion/optimization, Part C Combination therapy: Dose escalation, and Part D Combination therapy: Dose expansion/optimization. The interventions named are ARV-393 and Glofitamab, with Glofitamab appearing in the combination parts.
That layout suggests the study is first trying to find a usable dose and then widening the testing plan. In plain language, dose escalation means researchers start low and step up carefully, while expansion or optimization usually comes later to refine how the treatment is used.
Safety is the first question
The primary outcomes are all safety and tolerability measures. They include the Incidence of Dose Limiting Toxicities During First 28 Days, overall adverse events, abnormal vital signs, abnormal ECG readings (QT Interval), abnormal laboratory parameters, and Grade 3 or Grade 4 clinical lab abnormalities.
Those are the kinds of early checks that help researchers see whether a drug can be given safely and how the body reacts to it. The time frames also stay close to treatment, running from 28 days from first study dosing to 30 or 40 days after the last dose depending on the part of the study.
Why it fits the broader cancer update
This trial sits inside the Cancer Breakthroughs special event, alongside other recruiting or not-yet-recruiting cancer studies in the same period. Related registry observations in the event include studies in Non-Hodgkin lymphoma-adjacent treatment development, breast cancer, lung cancer, endometrial cancer, B-ALL, and other cancer settings.
The shared thread is early-stage testing, not confirmed success. For readers, that matters because a recruiting registry entry can show where researchers are placing their bets, but it does not say whether the approach will work once results are posted.